Post
The importance of AI in protecting hospitals from cyberattacks
Cyberattacks are especially dangerous when it comes to healthcare companies, as they collect and utilise sensitive patient data. For these organizations, …
Theolytics secures funds to advance oncolytic adenovirus therapy
UK-based biotechnology company Theolytics has concluded a funding round securing a total of £19m ($24.5m) to advance the development of …
Essential Pharma acquires Reminyl from Janssen Pharmaceutica
Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from Johnson & Johnson company Janssen Pharmaceutica. The …
TC-110 by Adaptimmune Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
TC-110 is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
B-Vaxx by Imugene for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
B-Vaxx is under clinical development by Imugene and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive …
SLATE-001 by Gritstone Bio for Gastrointestinal Tumor: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase …
SLATE-001 by Gritstone Bio for Metastatic Ovarian Cancer: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, …
SLATE-001 by Gritstone Bio for Metastatic Breast Cancer: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, …
Ftortiazinon by Gamaleya Federal Research Center of Epidemiology and Microbiology for Urinary Tract Infections: Likelihood of Approval
Ftortiazinon is under clinical development by Gamaleya Federal Research Center of Epidemiology and Microbiology and currently in Phase II for …
Rovadicitinib by Sino Biopharmaceutical for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
Rovadicitinib is under clinical development by Sino Biopharmaceutical and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase …
Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II …
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase …
Supernitro by Attgeno for Pulmonary Embolism: Likelihood of Approval
Supernitro is under clinical development by Attgeno and currently in Phase I for Pulmonary Embolism. According to GlobalData, Phase I …
RiMO-401 by Coordination Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
RiMO-401 is under clinical development by Coordination Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma …
KPG-121 by Kangpu Biopharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
KPG-121 is under clinical development by Kangpu Biopharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According …